All attendees must be “fully vaccinated” (as defined by the CDC at the time of the meeting) and must verify full COVID-19 vaccination status
to attend the 34th Annual Symposium & 32nd Annual Meeting in Phoenix. Proof of vaccination is required when registering for the meeting.

The PSG 32nd Annual Meeting

34th Annual Symposium

June 2-5, 2022

Phoenix, AZ

The meeting will get started in

Days
Hours
Minutes
Seconds

Meeting 2022 Abstract Submissions

Displaying 1 - 25 of 59

 ID Title Type of abstract Burton Deik Duda Sarva Yacoubian Mean Decision
422A Telehealth Psychotherapy Hub Improves Access to Mental Health Care for Rural Veterans with Parkinson’s DiseaseRegular Abstract12221.75Accept
421WATCH-PD: Remotely monitored sensor-based digital biomarkers of early PD statusLate Breaking Research Abstract22111.5Accept
420Hemifacial spasm associated with a caffeine-based weight loss supplement: a case report and review of the literatureRegular Abstract0010.333333333Reject
417Human Tissue Engineered Nigrostriatal Pathways Restore Axon Tracts to Improve Striatal Dopamine Levels in a Rat Model of Parkinson’s DiseaseLate Breaking Research Abstract2332.666666667Accept
416Efficacy of Deep Brain Stimulation on Perception of Pain IntensityRegular Abstract11111Accept
415Does total dietary protein intake affect motor and cognitive function in Parkinson’s Disease?Regular Abstract12111.25Accept
414Evaluating the Implementation and Impact of a Neurology Research Contact Registry on Recruitment for Parkinson’s disease Research StudiesRegular Abstract11111Accept
412Imaging caffeine-mediated blockade of striatal adenosine A2A receptors in LRRK2 G2019S carriersRegular Abstract12111.25Accept
411Effect of istradefylline dosage on unified Parkinsons’ disease rating scale (UPDRS) III-ON scores: Results from four randomized clinical trialsRegular Abstract12111.25Accept
410Optimizing patient-centric clinical outcome assessments for use in Parkinson’s disease clinical trials: Critical Path for Parkinson’s multistakeholder initiativeRegular Abstract010.5Accept
409Progression of gait disturbances in people with Parkinson’s disease and REM sleep without atoniaRegular Abstract12211.5Accept
408Caffeine Attenuates Lipopolysaccharide-induced Astrocytosis in LRRK2 G2019S Knock-in Mice.Regular Abstract11221.5Accept
404Vitamin B12 inhibits LRRK2 kinase activity in neuronal cells overexpressing the G2019S variant pathogenic for Parkinson’s diseaseRegular Abstract12211.5Accept
403Expanding clinical genetic testing and counseling to people with Parkinson’s disease: PD GENEration study updateLate Breaking Research Abstract1211.333333333Accept
401Investigating Conventional and Advanced Diffusion-MRI Measures to Understand White Matter Pathology in Parkinson’s disease Patients with Cognitive ImpairmentRegular Abstract11111Accept
400An agnostic pesticide-wide association approach to investigating agricultural pesticide use and Parkinson’s diseaseRegular Abstract12232Accept
399Development of a Novel Questionnaire on Women’s Health to Understand Its Role in Parkinson’s Disease Development and ProgressionRegular Abstract12211.5Accept
398Preliminary results from real-world data collection in RAD-PDRegular Abstract12211.5Accept
395Association between clinical motor symptoms and peripheral inflammatory cytokines after group therapeutic singing in persons with Parkinson’s diseaseRegular Abstract11111Accept
394Utilizing technology-based outcome measures in the natural setting to answer intriguing clinical questions in Parkinson diseaseRegular Abstract10100.5Accept
393Optimization of recruitment for movement disorders clinical trials in a pandemic: a single center experienceRegular Abstract11111Accept
392An experimental paradigm for testing effect of alternating-frequency Deep Brain Stimulation on gait, in Parkinson DiseaseRegular Abstract1211.333333333Accept
390Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD)Regular Abstract11111Accept
389A 104-week delayed-start analysis of PASADENA (Phase II study evaluating the safety and efficacy of prasinezumab in early-stage Parkinson’s disease)Regular Abstract13232.25
388Imaging regional histone deacetylase expression in dementia with Lewy bodies with [11C]Martinostat PETRegular Abstract12211.5
 ID Title Type of abstract Burton Deik Duda Sarva Yacoubian Mean Decision